ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853

Published: Apr 17, 2012

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics, today announced that the Investigational New Drug (IND) application for its IMGN853 product candidate is now active. IMGN853 is a potential new therapeutic for ovarian cancer, NSCLC, and other epithelial malignancies which over-express FOLR1. The Company expects Phase I evaluation of IMGN853 to begin in mid-2012.

Back to news